Gossamer Bio (NASDAQ: GOSS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 25 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $16.955 million which beat the analyst consensus estimate of $4.475 million by 278.88 percent. This is a 71.45 percent increase over sales of $9.889 million the same period last year.